Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)


Por: Gerdes, S, Velasco, M, Wu, J, Hubo, M and Veverka, K

Publicada: 17 nov 2021 Ahead of Print: 1 ene 2020
Categoría: Dermatology

Resumen:
Background: Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in real-world clinical practice. Methods: PubMed was searched for studies reporting real-world data in patients with psoriasis treated with Cal/BD aerosol foam. Results: Three large real-world studies with Cal/BD aerosol foam were identified: a prospective non-interventional study from Germany, a medical chart review from the US, and a retrospective non-interventional study from Spain. Some key findings included the following: high levels of adherence to treatment (82-93%); after 4 weeks, about 50% of patients achieved complete/almost complete responses; at final assessment, 85-95% of patients were extremely satisfied/very satisfied/satisfied with Cal/BD aerosol foam; all healthcare providers were satisfied or somewhat satisfied with the efficacy of Cal/BD foam and they reported similar findings for symptom improvements (itch, pain, erythema/redness, flaking, and plaque thickness). Global ratings by investigators/healthcare providers for symptom control, overall efficacy and the emotional status of patients were also very high (75-100%). Conclusion: The results from real-world studies undertaken in diverse healthcare systems reinforce the positive findings reported in RCTs with Cal/BD aerosol foam in patients with psoriasis.

Filiaciones:
Gerdes, S:
 Univ Med Ctr Schleswig Holstein, Dept Dermatol, Psoriasis Ctr, Campus Kiel, Kiel, Germany

:
 Hosp Arnau Vilanova, Valencia, Spain

Wu, J:
 Dermatol Res & Educ Fdn, Irvine, CA USA

Hubo, M:
 LEO Pharma GmbH, Neu Isenburg, Germany

Veverka, K:
 LEO Pharma Inc, Madison, NJ USA
ISSN: 09546634





JOURNAL OF DERMATOLOGICAL TREATMENT
Editorial
TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 32 Número: 8
Páginas: 883-893
WOS Id: 000512382200001
ID de PubMed: 31986945

MÉTRICAS